Disappointment over PBS rejection of immunotherapies for melanoma

The PBAC has recommended the PBS listing of dabrafenib in combination with trametinib as adjuvant treatment for patients who have had completely resected BRAF V600 mutation positive Stage IIIB, IIIC or IIID malignant melanoma. A summary document of outcomes from the July PBAC meeting released last week said the Committee was satisfied that the targeted ...

Already a member?

Login to keep reading.

© 2021 the limbic